image
Healthcare - Biotechnology - NASDAQ - US
$ 6.02
-3.06 %
$ 1.83 B
Market Cap
-4.07
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 31, 2025.

The intrinsic value of one IOVA stock under the worst case scenario is HIDDEN Compared to the current market price of 6.02 USD, Iovance Biotherapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 31, 2025.

The intrinsic value of one IOVA stock under the base case scenario is HIDDEN Compared to the current market price of 6.02 USD, Iovance Biotherapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 31, 2025.

The intrinsic value of one IOVA stock under the best case scenario is HIDDEN Compared to the current market price of 6.02 USD, Iovance Biotherapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
1.19 M REVENUE
0.00%
-461 M OPERATING INCOME
-15.46%
-444 M NET INCOME
-12.16%
-362 M OPERATING CASH FLOW
-23.59%
-155 M INVESTING CASH FLOW
-60.53%
463 M FINANCING CASH FLOW
143.47%
58.6 M REVENUE
88.24%
-89.1 M OPERATING INCOME
12.61%
-83.5 M NET INCOME
13.96%
-59 M OPERATING CASH FLOW
40.09%
-48.8 M INVESTING CASH FLOW
-121.34%
42 M FINANCING CASH FLOW
-72.55%
Balance Sheet Iovance Biotherapeutics, Inc.
image
Current Assets 308 M
Cash & Short-Term Investments 280 M
Receivables 151 K
Other Current Assets 27.8 M
Non-Current Assets 473 M
Long-Term Investments 0
PP&E 177 M
Other Non-Current Assets 296 M
Current Liabilities 110 M
Accounts Payable 33.1 M
Short-Term Debt 7.78 M
Other Current Liabilities 69.4 M
Non-Current Liabilities 85.4 M
Long-Term Debt 68.1 M
Other Non-Current Liabilities 17.3 M
EFFICIENCY
Earnings Waterfall Iovance Biotherapeutics, Inc.
image
Revenue 1.19 M
Cost Of Revenue 10.8 M
Gross Profit -9.57 M
Operating Expenses 451 M
Operating Income -461 M
Other Expenses -16.5 M
Net Income -444 M
RATIOS
-804.54% GROSS MARGIN
-804.54%
-38734.99% OPERATING MARGIN
-38734.99%
-37345.42% NET MARGIN
-37345.42%
-75.95% ROE
-75.95%
-56.90% ROA
-56.90%
-67.42% ROIC
-67.42%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Iovance Biotherapeutics, Inc.
image
Net Income -444 M
Depreciation & Amortization 33.1 M
Capital Expenditures -22.3 M
Stock-Based Compensation 62.6 M
Change in Working Capital -6.52 M
Others -4.62 M
Free Cash Flow -384 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Iovance Biotherapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for IOVA of $20.6 , with forecasts ranging from a low of $10 to a high of $28 .
IOVA Lowest Price Target Wall Street Target
10 USD 66.11%
IOVA Average Price Target Wall Street Target
20.6 USD 241.72%
IOVA Highest Price Target Wall Street Target
28 USD 365.12%
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Iovance Biotherapeutics, Inc.
image
Sold
0-3 MONTHS
503 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
48.3 M USD 3
9-12 MONTHS
Date Value Insider Amount Avg Price
2 months ago
Nov 12, 2024
Sell 503 K USD
Maynard Ryan D
Director
- 50000
10.06 USD
11 months ago
Feb 20, 2024
Bought 2.29 M USD
MCPEAK MERRILL A
Director
+ 250000
9.15 USD
11 months ago
Feb 20, 2024
Bought 293 K USD
Dukes Iain D.
Director
+ 32000
9.15 USD
11 months ago
Feb 20, 2024
Bought 45.8 M USD
Rothbaum Wayne P.
Director
+ 5000000
9.15 USD
1 year ago
Sep 18, 2023
Bought 55.6 K USD
MCPEAK MERRILL A
Director
+ 10000
5.56 USD
1 year ago
Sep 15, 2023
Bought 26.5 M USD
Rothbaum Wayne P.
Director
+ 5000000
5.3 USD
2 years ago
Dec 21, 2022
Bought 61.5 K USD
MCPEAK MERRILL A
Director
+ 10000
6.15 USD
2 years ago
Dec 02, 2022
Bought 65 M USD
Rothbaum Wayne P.
Director
+ 10000000
6.5 USD
2 years ago
Nov 29, 2022
Bought 63.1 K USD
MCPEAK MERRILL A
Director
+ 10000
6.31 USD
2 years ago
Nov 28, 2022
Bought 5.98 K USD
Vogt Frederick G
Interim CEO & General Counsel
+ 1000
5.98 USD
2 years ago
Nov 28, 2022
Bought 61.8 K USD
MCPEAK MERRILL A
Director
+ 10000
6.18 USD
2 years ago
Nov 23, 2022
Bought 61 K USD
Dukes Iain D.
Director
+ 10000
6.1 USD
2 years ago
May 31, 2022
Bought 68 K USD
MCPEAK MERRILL A
Director
+ 10000
6.8 USD
2 years ago
May 31, 2022
Bought 68.4 K USD
MCPEAK MERRILL A
director:
+ 10000
6.84 USD
2 years ago
May 31, 2022
Bought 50.6 K USD
Maynard Ryan D
director:
+ 7500
6.745 USD
2 years ago
May 31, 2022
Bought 53.1 K USD
WEISER MICHAEL
Director
+ 7813
6.8 USD
2 years ago
May 31, 2022
Bought 14.8 K USD
WEISER MICHAEL
director:
+ 2187
6.79 USD
2 years ago
Jun 01, 2022
Bought 6.44 K USD
Vogt Frederick G
Interim CEO & General Counsel
+ 1000
6.44 USD
2 years ago
Jun 01, 2022
Bought 3.22 M USD
Rothbaum Wayne P.
Director
+ 500000
6.431 USD
2 years ago
May 31, 2022
Bought 3.38 M USD
Rothbaum Wayne P.
director:
+ 500000
6.7691 USD
6 years ago
Dec 18, 2018
Bought 104 K USD
Dukes Iain D.
Director
+ 12000
8.6497 USD
6 years ago
Dec 13, 2018
Bought 96.3 K USD
MCPEAK MERRILL A
Director
+ 10000
9.6273 USD
6 years ago
Dec 06, 2018
Bought 2.96 M USD
Rothbaum Wayne P.
Director
+ 300000
9.86 USD
6 years ago
Dec 04, 2018
Bought 9.5 M USD
Rothbaum Wayne P.
Director
+ 921053
10.31 USD
8 years ago
Aug 24, 2016
Sell 305 K USD
Hillsberg Sanford
Director
- 33500
9.0985 USD
8 years ago
Aug 25, 2016
Sell 179 K USD
Hillsberg Sanford
Director
- 20500
8.7128 USD
8 years ago
Aug 22, 2016
Sell 492 K USD
Hillsberg Sanford
Director
- 54000
9.1063 USD
9 years ago
Sep 04, 2015
Sell 109 K USD
Hillsberg Sanford
Director
- 16000
6.84 USD
9 years ago
Sep 08, 2015
Sell 118 K USD
Hillsberg Sanford
Director
- 16500
7.13 USD
9 years ago
Aug 03, 2015
Sell 265 K USD
Hillsberg Sanford
Director
- 32500
8.15 USD
9 years ago
May 01, 2015
Sell 26.8 M USD
Ayer Capital Management, LP
10 percent owner
- 2780682
9.6208 USD
9 years ago
May 06, 2015
Sell 500 K USD
Hillsberg Sanford
Director
- 50000
10 USD
10 years ago
Nov 06, 2014
Sell 69 B USD
BRISTOL INVESTMENT FUND LTD
10 percent owner
- 100000
690000 USD
11 years ago
Nov 05, 2013
Bought 100 K USD
MCPEAK MERRILL A/
Director
+ 50000
2 USD
11 years ago
Nov 05, 2013
Bought 250 K USD
Singh Manish
President & CEO
+ 125000
2 USD
13 years ago
Aug 22, 2011
Bought 1 K USD
Schroeder Martin
Director
+ 1000000
0.001 USD
13 years ago
Jul 21, 2011
Bought 14 K USD
MCPEAK MERRILL A/
Director
+ 10000
1.4 USD
7. News
3 Stocks That Could Turn $1,000 Into $5,000 by 2030 Finding the market's highest-growth prospects at any given time isn't terribly tough to do. Finding stocks capable of quintupling in value over the course of the coming five years, however, is a different story. fool.com - 1 week ago
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SAN CARLOS, Calif., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on January 16, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 224,550 shares of Iovance's common stock to forty-one new, non-executive employees. globenewswire.com - 2 weeks ago
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025 This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 billion by 2028. Every year, the FDA and EMA approve dozens of anticancer drugs, so Seeking Alpha readers should be careful when making decisions. seekingalpha.com - 2 weeks ago
3 Mid-Cap Stocks That Could Take Off in 2025 Some of the best possible returns for investors come by not going after megacaps, but instead pursuing stocks that have more modest valuations. Mid-cap stocks represent companies valued at between $2 billion and $10 billion. fool.com - 3 weeks ago
Why Iovance Biotherapeutics Stock Zoomed More Than 5% Higher Today Now this is a fine way for a stock to greet the new year. On the back of a glowing analyst recommendation, Iovance Biotherapeutics's (IOVA 5.27%) shares closed Thursday more than 5% higher in price. fool.com - 4 weeks ago
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SAN CARLOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on December 19, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 203,980 shares of Iovance's common stock to forty-eight new, non-executive employees. globenewswire.com - 1 month ago
If I Could Only Buy 3 Stocks in the Last Month of 2024, I'd Pick These Investors are fortunate to have access to a universe of stocks that they can buy or sell at any given time. Sometimes, however, limiting your options can be a powerful exercise. fool.com - 1 month ago
2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio? Investors looking for stocks that can make dramatic gains can find some in the biopharmaceutical industry. Right now, there are a pair of biopharma stocks that Wall Street expects to rocket higher in 2025. fool.com - 1 month ago
Prediction: This Stock Will Beat the Market in 2025 It hasn't been a great year for Iovance Biotherapeutics (IOVA -1.40%), an innovative mid-cap biotech company. The drugmaker's shares have significantly lagged the market -- advancing only about 5% so far this year. fool.com - 1 month ago
3 Monster Stocks to Hold for the Next 10 Years It's usually not difficult to find a compelling growth stock to step into. Choosing a growth stock you're confident holding onto for a decade or more, however, is a different story. fool.com - 1 month ago
Is Iovance Biotherapeutics Stock a Millionaire Maker? The biotech industry has been described as the Wild West of the stock market. Although some companies manage to develop and commercialize a life-changing therapeutic, countless more start-ups inevitably fail. fool.com - 2 months ago
Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer SAN CARLOS, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that Raj Puri, M.D., Ph.D. has been promoted to the newly created role of Chief Regulatory Officer. Dr. Puri joined Iovance in March 2022 as Executive Vice President, Regulatory Strategy and Translational Medicine. globenewswire.com - 2 months ago
8. Profile Summary

Iovance Biotherapeutics, Inc. IOVA

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 1.83 B
Dividend Yield 0.00%
Description Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Contact 825 Industrial Road, San Carlos, CA, 94070 https://www.iovance.com
IPO Date Oct. 15, 2010
Employees 557
Officers Mr. Brian Shew M.B.A. Senior Vice President & Head of Digital and Information Technology Mr. Howard B. Johnson M.B.A. Chief Business Officer Dr. Frederick G. Vogt Esq., J.D., Ph.D. Interim Chief Executive Officer, President, General Counsel, Corporate Secretary & Director Mr. Jean-Marc Bellemin M.B.A. Chief Financial Officer, Principal Accounting Officer & Treasurer Dr. Raj K. Puri M.D., Ph.D. Chief Regulatory Officer Dr. Friedrich Graf Finckenstein M.D. Chief Medical Officer Ms. Sara Pellegrino Vice President of Investor Relations & Public Relations Ms. Tracy Winton Executive Vice President of Human Resources Dr. Igor P. Bilinsky Ph.D. Chief Operating Officer Mr. Kevin Smyth Executive Vice President of Quality